The Incidence of AIDS-De fi ning Illnesses at a Current CD 4 Count ≥ 200 Cells / μ L in the Post – Combination Antiretroviral Therapy Era

A. Mocroft, H. J. Furrer, J. M. Miro, P. Reiss, C. Mussini, O. Kirk, S. Abgrall, S. Ayayi, B. Bartmeyer, D. Braun, A. Castagna, A. d’Arminio Monforte, B. Gazzard, F. Gutierrez, I. Hurtado, K. Jansen, L. Meyer, P. Muñoz, N. Obel, P. Soler-Palacin, A. Papadopoulos, F. Raffi, J. T. Ramos, J. K. Rockstroh, D. Salmon, C. Torti, J. Warszawski, S. de Wit, R. Zangerle, C. Fabre-Colin, J. Kjaer, G. Chene, J. Grarup, and J. D. Lundgren; for the Opportunistic Infections Working Group on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCOORD Department of Infection and Population Health, University College London, United Kingdom; Department of Infectious Diseases, Bern University Hospital and University of Bern, Switzerland; Hospital Clinic–IDIBAPS, University of Barcelona, Spain; Academisch Medisch Centrum bij de Universiteit van Amsterdam; Stichting HIV Monitoring, Amsterdam, The Netherlands; Università Modena, Italy; Copenhagen HIV Programme, and Department of Infectious Diseases, Copenhagen University Hospital/Rigshospitalet, Denmark; UPMC, Université Paris 06, and INSERM, UMR_S 943, and AP-HP, Hôpital Avicenne, Services des Maladies Infectieuses et Tropicales, Paris, and CHU de Bordeaux and INSERM U897, Bordeaux, France; Department of Infectious Disease, Robert Koch-Institute, Berlin, Germany; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland; Department of Infectious Diseases IRCCS San Raffaele, and Department of Health Sciences, Institute of Infectious Diseases, Milan, Italy; St Stephen’s Clinic, Chelsea and Westminster Hospital, London, United Kingdom; Infectious Diseases Unit, Hospital General Universitario de Elche, Universidad Miguel Hernández, Alicante, and Centro Superior de Investigación en Salud Pública (CSISP-FISABIO), Red de Investigacion en Servicios de Salud en Enfermedades Cronicas (REDISSEC), Valencia, Spain; Competence Network for HIV/AIDS, St Josef-Clinic, RuhrUniversity, Bochum, Germany; CESP Centre for Research in Epidemiology and Population Health, INSERM U1018, Paris, and Epidemiology and Public Health Service, AP-HP, Hopital Bicêtre, Le Kremlin Bicêtre, France; Departament of Infectious Diseases, Hospital Universitario de Basurto, Bilbao, and Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Spain; University of Athens Medical School, University General Hospital “ATTIKON,” Greece; University Hospital, Hotel Dieu, Nantes, France; Hospital Universitario de Getafe, Madrid, Spain; Medizinische Universitäts Klinik I, University of Bonn, Germany; Department of Internal Medicine and Infectious Diseases, Cochin Hospital, Paris, France; University Division of Infectious and Tropical Diseases, University and Spedali Civili of Brescia, and Department of Medical and Surgical Sciences, Unit of Infectious Diseases, University “Magna Graecia,” Catanzaro, Italy; AP-HP Public Health Department, INSERM CESP U1018, Université Paris-Sud, Le KremlinBicêtre, France; Saint-Pierre Hospital, Brussels, Belgium; Medical University Innsbruck, Austria; Centre INSERM U897-Epidémiologie Statistique, Université de Bordeaux, ISPED, and INSERM, ISPED, Centre INSERM U897-Epidémiologie Statistique, Bordeaux, France

[1]  A. Justice,et al.  Lessons learned from the first wave of aging with HIV , 2012, AIDS.

[2]  A. Mocroft,et al.  Regional Differences in AIDS and Non-AIDS Related Mortality in HIV-Positive Individuals across Europe and Argentina: The EuroSIDA Study , 2012, PLoS ONE.

[3]  R. Écochard,et al.  Response to antiretroviral therapy: improved survival associated with CD4 above 500 cells/&mgr;l , 2012, AIDS.

[4]  Mardge H. Cohen,et al.  HIV and Aging: State of Knowledge and Areas of Critical Need for Research. A Report to the NIH Office of AIDS Research by the HIV and Aging Working Group , 2012, Journal of acquired immune deficiency syndromes.

[5]  B. Gazzard,et al.  CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE , 2012, PLoS medicine.

[6]  K. Freedberg,et al.  AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  A. Mocroft,et al.  Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata , 2011, AIDS.

[8]  Richard D Moore,et al.  Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  P. Reiss,et al.  Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  H. Kessler,et al.  Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution , 2010, AIDS research and therapy.

[11]  A. Mocroft,et al.  Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe , 2010, Journal of acquired immune deficiency syndromes.

[12]  M. Guiguet,et al.  Kaposi Sarcoma Incidence and Survival Among HIV-Infected Homosexual Men After HIV Seroconversion , 2010, Journal of the National Cancer Institute.

[13]  M. Guiguet,et al.  Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. , 2009, The Lancet. Oncology.

[14]  A. Phillips,et al.  HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity , 2009, BMJ : British Medical Journal.

[15]  Lewis H Kuller,et al.  Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection , 2008, PLoS medicine.

[16]  A. Mocroft,et al.  The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe--a review of published results. , 2008, Central European journal of public health.

[17]  D Costagliola,et al.  Causes of the first AIDS‐defining illness and subsequent survival before and after the advent of combined antiretroviral therapy * , 2008, HIV Medicine.

[18]  N. Probst-Hensch,et al.  Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy , 2008, AIDS.

[19]  B. Gazzard,et al.  Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count , 2007, AIDS.

[20]  J. Sterne,et al.  Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies , 2007, AIDS.

[21]  A. Mocroft,et al.  Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study. , 2006, The Journal of infectious diseases.

[22]  J. Gatell,et al.  Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. , 2006, Archives of internal medicine.

[23]  Martin Meier-Schellersheim,et al.  Pathogenesis of HIV infection: what the virus spares is as important as what it destroys , 2006, Nature Medicine.

[24]  B. Ledergerber,et al.  HIV Cohort Collaborations: Proposal for Harmonization of Data Exchange , 2004, Antiviral therapy.

[25]  A. Mocroft,et al.  Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD. , 2000, American journal of respiratory and critical care medicine.

[26]  A. Mocroft,et al.  AIDS across Europe, 1994–98: the EuroSIDA study , 2000, The Lancet.

[27]  M Egger,et al.  AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. , 1999, JAMA.

[28]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[29]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[30]  B. Gazzard,et al.  The incidence of AIDS-defining illnesses in 4883 patients with human immunodeficiency virus infection , 1998 .

[31]  Manuel Battegay,et al.  Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study , 1997, BMJ.

[32]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[33]  A. Phillips,et al.  Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. , 1996, Genitourinary medicine.

[34]  B. Thiers,et al.  CD4+ Count–Guided Interruption of Antiretroviral Treatment , 2007 .